MINI LONG ZERTIFIKAT - NOVO-NORDISK B | Market Closed - Börse Stuttgart 04:09:54 2024-04-29 EDT | ||
| 21.92 EUR | +2.00% |
|
| Current month | -0.41% | ||
| 1 month | -0.41% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
NOVO NORDISK A/S
Latest news about NOVO NORDISK A/S
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-04-29 | 21.92 | +2.00% | 0 |
| 24-04-26 | 21.49 | +0.61% | 0 |
| 24-04-25 | 21.36 | -2.82% | 0 |
| 24-04-24 | 21.98 | +1.43% | 0 |
| 24-04-23 | 21.67 | +3.04% | 0 |
Delayed Quote Börse Stuttgart
Last update April 29, 2024 at 04:09 am
More quotesStatic data
| Product type | Knock-Out mit Stop Loss |
|---|---|
| Buy / Sell | CALL |
| Underlying | NOVO NORDISK A/S |
| Issuer | 
BNP Paribas
|
| WKN | AA8L6C |
| ISIN | DE000AA8L6C6 |
| Date issued | 2014-02-18 |
| Strike | 69.55 kr |
| Maturity | Unlimited |
| Parity | 5 : 1 |
| Emission price | 0.62 € |
| Emission volume | N/A |
| Settlement | Barausgleich |
| Currency | EUR |
Technical Indicators
| Highest since issue | 22.74 € |
|---|---|
| Lowest since issue | 0.5 € |
Company Profile
Novo Nordisk A/S specializes in the design, manufacture and marketing of pharmaceutical products. Net sales break down by family of products as follows:
- diabetes and obesity treatment products (92.6%);
- rare disease treatment products (7.4%): intended for the treatment of haemophilia, blood disorders, hormonal disorders, etc.
Net sales are distributed geographically as follows: Europe/Middle East/Africa (21.9%), the United States (54.9%), North America (3.9%), China (7.2%) and other (12.1%).
Sector
-
Consensus: Novo Nordisk A/S
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
25
Last Close Price
902.6
DKK
Average target price
904.2
DKK
Spread / Average Target
+0.18%
- Stock Market
- Certificates
- Certificat
